Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 Price-to-Tangible-Book is 12.22 as of Jul. 19, 2026, which is 29% below its 10-year median of 17.27. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.38 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 701 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 89.44% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Price-to-Tangible-Book or its related term are showing as below:
XVIPF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 8.21 Med: 17.27 Max: 35.04
Current: 11.74
During the past 13 years, Xvivo Perfusion AB's highest Price to Tangible Book Ratio was 35.04. The lowest was 8.21. And the median was 17.27.
XVIPF's Price-to-Tangible-Book is ranked worse than 89.44% of 701
companies
in the Medical Devices & Instruments industry
Industry Median: 2.59
vs XVIPF: 11.74
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Xvivo Perfusion AB Price-to-Tangible-Book Related Terms
Xvivo Perfusion AB Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Xvivo Perfusion AB (XVIPF) has a Price-to-Tangible-Book of 12.22 as of Jul. 19, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Xvivo Perfusion AB and its competitors. This is 29% below median its historical median of 17.27. Over the past decade, Xvivo Perfusion AB's Price-to-Tangible-Book has ranged from 8.21 to 35.04. According to the industry distribution chart, Xvivo Perfusion AB ranks #627 out of 701 companies in the Medical Devices & Instruments industry, placing it in the top 89.4%.
Is Xvivo Perfusion AB's Price-to-Tangible-Book too high?
Xvivo Perfusion AB's current Price-to-Tangible-Book of 12.22 is 29% below median its 10-year median of 17.27. Over the past 10 years, this metric has ranged from a low of 8.21 to a high of 35.04. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.59. Xvivo Perfusion AB's value of 12.22 is 371.8% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #627 out of 701 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #627 out of 701 companies for Price-to-Tangible-Book. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.59. Xvivo Perfusion AB's value of 12.22 is 371.8% above this benchmark. Historically, Xvivo Perfusion AB's own Price-to-Tangible-Book has ranged from 8.21 to 35.04 over the past decade. While the company's 10-year median is 17.27 vs. the industry median of 2.59, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.59, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Price-to-Tangible-Book of 12.22 is 371.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Price-to-Tangible-Book is 12.22, which is 29% below median its own 10-year median of 17.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.38, compared to a current price of $26.07 — trading 41.3% below its estimated fair value. The current Price-to-Tangible-Book is 12.22, which is 29% below median its 10-year median of 17.27 and 371.8% above the Medical Devices & Instruments industry median of 2.59. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Price-to-Tangible-Book is 12.22 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $26.07 is trading 41.3% below its estimated GF Value™ of $44.38.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Price-to-Tangible-Book: 12.22 (29% below median its 10-year median of 17.27)
GF Value™: $44.38 vs. price of $26.07 (41.3% below fair value)
Industry Position: 371.8% above the Medical Devices & Instruments median (#627 of 701)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
